<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Two hundred and eight cases of B-cell non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (B-NHL) occurring in Europeans without any signs of <z:e sem="disease" ids="C0019693" disease_type="Disease or Syndrome" abbrv="">HIV infection</z:e> were investigated for their association with an Epstein-Barr virus (EBV) <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The polymerase chain reaction (PCR) was applied for EBV-DNA detection, in situ hybridization (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ISH</z:e>) for the cellular localization of EBV-encoded small nuclear <z:chebi fb="40" ids="33697">RNAs</z:chebi> (EBER) and immediate-early <z:chebi fb="40" ids="33697">RNAs</z:chebi> (BHLF), and immunohistology (IH) for the detection of EBV-encoded latent membrane protein (LMP) and EBV nuclear antigen 2 (EBNA2) expression </plain></SENT>
<SENT sid="2" pm="."><plain>PCR and EBER-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ISH</z:e> produced congruent results in those cases with amplifiable DNA </plain></SENT>
<SENT sid="3" pm="."><plain>EBV was present overall in 26 per cent (54/208) of the B-NHL cases </plain></SENT>
<SENT sid="4" pm="."><plain>Through EBER-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ISH</z:e>, the virus could be localized merely in rare non-neoplastic bystander lymphocytes in 27 and additionally in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells of 27 cases </plain></SENT>
<SENT sid="5" pm="."><plain>Unexpectedly, the proportion of EBV-infected <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells present in the different cases varied between 1 and 100 per cent </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> but three of the cases with infected <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells were of high-grade <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Correlation with the morphological and immunological <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> phenotype revealed that <z:hpo ids='HP_0000001'>all</z:hpo> cases with more than 80 per cent EBER-positive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells were either B-anaplastic large cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (B-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALCL</z:e>), <z:hpo ids='HP_0003745'>sporadic</z:hpo> Burkitt's <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, or B-NHLs with partial or full plasmacellular differentiation </plain></SENT>
<SENT sid="8" pm="."><plain>LMP was consistently absent from Burkitt's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> and constantly expressed in B-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ALCLs</z:e> with EBER-positive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells, while in <z:hpo ids='HP_0000001'>all</z:hpo> other instances it varied greatly and was rarer than EBER expression.(ABSTRACT TRUNCATED AT 250 WORDS) </plain></SENT>
</text></document>